Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 3, 2014

View Archived Issues

Agilis and Intrexon collaborate on DNA-based therapeutics for Friedreich's ataxia

Oprozomib shows antitumor activity in phase I/II trials in patients with hematologic malignancies

TD-6450 demonstrates improved potency against genotype 1a-resistant mutants

Karyopharm presents results from phase I study of selinexor in hematological cancers

Meiji Seika Pharma begins phase II study of ME-1111

ASTX-727 demonstrates promising preclinical pharmacokinetic profile

ProNAi Therapeutics presents promising phase II data for PNT-2258

Japanese researchers prepare new agents for diabetes and other metabolic disorders

Janssen R&D Ireland patents novel agents for RSV infection

Novel neprilysin inhibitor prodrugs disclosed by Theravance

Georgia State University divulges novel agents for bacterial infections

Cerenis reports topline data for CER-001

Eisai launches Fycompa for partial-onset seizures in patients with epilepsy

IRM synthesizes novel EGFR inhibitors for cancer

NPS Pharmaceuticals begins registration study of teduglutide in pediatric patients

Horizon-labeled Vimovo now available in the U.S.

Incyte presents interim phase II results for INCB-039110 in patients with primary myelofibrosis

Marina Biotech and Mirna Therapeutics amend agreement for microRNA therapeutics

GlaxoSmithKline presents early clinical data for afuresertib

Sanofi presents phase II data for SAR-3419 and rituximab combination in B-cell lymphoma

Probiodrug transfers CDK9 inhibitor program to AstraZeneca

Salix Pharmaceuticals completes acquisition of Santarus

Enrollment open in phase IIa study of THR-18 in stroke patients treated with tPA

Sanofi expands access to data from clinical trials

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...